⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 13, 2024Journal of Medicinal Chemistry

Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity

Fang Yang Qianmeng Lin Xiaojuan Song Huisi Huang Xiaojuan Chen Jianwen Tan Yun Li Yang Zhou Zhengchao Tu Hongli Du Zhimin Zhang Raquel Ortega Xiaojing Lin Adam V. Patterson Jeff B. Smaill Yongheng Chen Xiaoyun Lu

View Full Paper

Ask AI

Bookmark

Share

Abstract

Fibroblast growth factor receptor 4 (FGFR4) has been considered as a potential anticancer target due to FGF19/FGFR4 mediated aberrant signaling in hepatocellular carcinoma (HCC). Several FGFR4 inhibitors have been reported, but none have gained approval. Herein, a series of 5-formyl-pyrrolo[3,2-

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yang et al. (2024) studied this question.

synapsesocial.com/papers/68e79572b6db64358770613d https://doi.org/10.1021/acs.jmedchem.3c01810

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma2024 · 10 citations
2Discovery of novel FGFR4 inhibitors through a build-up fragment strategy2024 · 1 citations
3Fibroblast growth factor 19-fibroblast growth factor receptor 4 axis: From oncogenesis to targeted-immunotherapy in advanced hepatocellular carcinoma2025 · 5 citations
4AI-Driven discovery and experimental validation of covalent FGFR4 inhibitors for hepatocellular carcinomaOriginal Research · 2026
5Selection and Optimization of a High-Affinity FGFR4 Aptamer that Blocks FGF19–FGFR4 SignalingOriginal Research · 2026